Trotana Therapeutics

What Trotana Therapeutics does

Trotana Therapeutics (legal entity Trotana, Inc.) is a privately held, pre-revenue biotechnology company headquartered in San Diego, California, developing orally-dosed small molecule therapeutics for inflammatory diseases. The company is differentiated by its focus on RNA-binding proteins (RBPs) — a relatively underexplored target class — and by its proprietary drug discovery platform called RiME (RNA binding protein modulator engine), which has already generated orally bioavailable RBP-targeted molecules. RiME prioritizes RBP targets that control expression of known disease-driving inflammatory proteins and regulate immune cell fate in patients with inflammation, and is being used to expand a proprietary pipeline of anti-inflammatory drug candidates. The company was co-founded by Gene Yeo and Frank Furnari, leveraging deep RBP biology expertise, and is backed by Lightstone Ventures as lead investor following a $52.5 million Series A financing closed in February 2025.

The business model is a classic clinical-stage biotech R&D structure: Trotana does not yet commercialize any products, has no disclosed pricing, and operates a corporate website (trotana.com) primarily as an informational channel with sections for About, Science, Pipeline, News, Careers, and Contact Us. Revenue, when it eventually materializes, is anticipated through pharmaceutical product sales or licensing following regulatory approval of pipeline candidates — at present the website displays a 'Coming Soon' message and leadership biographies are placeholder content, indicating the company is in stealth or very early buildout mode despite the Series A close. The end customer is patients with inflammatory diseases, accessed indirectly through future commercialization channels rather than direct B2B or B2C relationships today.

Name

Trotana Therapeutics

Legal name

Trotana, Inc.

Website

https://trotana.com

Company type

Private

Founded year

2019

Operating status

Operating

Headcount range

11–50 employees

Short description

Trotana Therapeutics is a pre-revenue, San Diego-based biotech developing orally-dosed small molecule anti-inflammatory medicines that target human RNA-binding proteins via its proprietary RiME drug discovery platform, founded by Gene Yeo and Frank Furnari and backed by Lightstone Ventures.

Ownership category

akta.pro rank

Product category

Anti-inflammatory Biopharmaceuticals

NAICS

Other Scientific and Technical Consulting Services (54169), Other Scientific and Technical Consulting Services (541690)

SIC

Medicinal Chemicals & Botanical Products (2833)

akta.pro primary industry

RNA Therapeutics Platforms & Design (sequence design, target ID/validation, AI/bioinformatics) (HLAAADAG)

akta.pro secondary industry

RNA Chemistry & Oligonucleotide Engineering (backbones, modifications, stereochemistry) (HLAAADAE)

Keywords

• RNA binding proteins
• Small molecule therapeutics
• Anti-inflammatory medicines
• Oral drug discovery
• Biotechnology platform

Headquarters

HQ city

San Diego

HQ country

United States

HQ region

North America

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Operations, Others, Marketing or Sales

Revenue model

1. Drug Development and Commercialization: Pre-revenue biotechnology company developing novel oral anti-inflammatory medicines. As a clinical-stage biotech, revenue generation is anticipated through eventual pharmaceutical product sales following regulatory approval and commercialization of pipeline candidates.

Marketing channels1 record

Core offering

Trotana Therapeutics is a clinical-stage biotechnology company that discovers and develops orally-dosed small molecule therapeutics targeting human RNA binding proteins (RBPs) for the treatment of inflammatory diseases. Its proprietary RiME (RNA binding protein modulator engine) platform is used to identify RBP targets controlling disease-driving inflammatory proteins and immune cell fate, and to expand a proprietary pipeline of oral anti-inflammatory drug candidates.

Product overview

Trotana Therapeutics is a single-platform biotechnology company developing novel oral anti-inflammatory medicines. The company's core offering is the RiME (RNA binding protein modulator engine) platform, which is utilized to expand their proprietary pipeline of small molecule drugs targeting RBPs. The platform generates orally-dosed therapeutics that control expression of disease-driving inflammatory proteins and regulate immune cell fate in patients with inflammation.

Differentiator

Problem solved

Functional benefit

Products and services

• RiME (RNA binding protein modulator engine) Proprietary drug discovery platform used internally by Trotana to generate orally-dosed small molecule therapeutics that target human RNA binding proteins controlling expression of disease-driving inflammatory proteins and immune cell fate in patients with inflammation.

Segments1 record

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature1 record

Scale indicators1 record

Recent moves4 records

Expansion highlights4 records

Direct peers

• Arrakis Therapeutics: Pioneer in small-molecule drugs that directly target RNA, with a platform (rSM) that overlaps conceptually with Trotana's RiME engine for drugging RNA-related biology with orally bioavailable molecules.
• Accent Therapeutics: Develops small-molecule therapies against RNA-modifying proteins (e.g., METTL3, METTL5), directly comparable to Trotana's RBP-targeting strategy in the RNA regulatory protein space.
• Skyhawk Therapeutics: Builds small molecules that modulate RNA splicing and RNA-binding protein interactions, sharing Trotana's thesis that RNA biology can be addressed with oral small molecules.
• Expansion Therapeutics: Focused on RNA-targeted small molecules for repeat-expansion diseases, applying medicinal chemistry to RNA-binding mechanisms that overlap with Trotana's RBP focus.
• Ribometrix: Discovers small molecules that target functional RNA structures and RNA-binding interactions, a closely adjacent platform to Trotana's RBP modulators.
• Storm Therapeutics: Pioneers small-molecule inhibitors of RNA-modifying enzymes, with a comparable approach of drugging the RNA regulatory machinery that Trotana targets via RiME.

Broad incumbents

• Eisai: Large pharmaceutical company with established inflammation and immunology franchises (e.g., etanercept partnerships), representing the kind of broad incumbent Trotana's oral RBP candidates would eventually compete with or partner into.
• AbbVie: Major inflammation/immunology player (Humira, Skyrizi, Rinvoq) and likely potential partner or acquirer for differentiated oral anti-inflammatory mechanisms like Trotana's.

Emerging players

• Locanabio: RNA-targeting therapeutics company co-founded by Gene Yeo (also a Trotana co-founder), providing a thematic link to Trotana through overlapping RNA-biology science networks.
• Eclipse Bioinnovations: RNA genomics tools company also co-founded by Gene Yeo, connected to Trotana through shared scientific lineage in RNA-binding protein biology.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks4 records

Key highlights5 records

Customer concentration

• Xx.com/trotanatx
• LinkedInlinkedin.com/company/trotana-inc

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Funding overview

Funding rounds1 record

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Trotana Therapeutics